Independent Non-Executive Director of Radiopharm Theranostics Picks Up 48% More Stock
Even if it's not a huge purchase, we think it was good to see that Ian Turner, the Independent Non-Executive Director of Radiopharm Theranostics Limited (ASX:RAD) recently shelled out AU$87k to buy stock, at AU$0.029 per share. That purchase might not be huge but it did increase their holding by 48%.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
The MD, CEO & Director Riccardo Canevari made the biggest insider purchase in the last 12 months. That single transaction was for AU$241k worth of shares at a price of AU$0.031 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being AU$0.024). It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
In the last twelve months insiders purchased 22.43m shares for AU$772k. But insiders sold 1.50m shares worth AU$43k. Overall, Radiopharm Theranostics insiders were net buyers during the last year. Their average price was about AU$0.034. These transactions suggest that insiders have considered the current price attractive. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Radiopharm Theranostics
Radiopharm Theranostics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. From our data, it seems that Radiopharm Theranostics insiders own 11% of the company, worth about AU$6.3m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Radiopharm Theranostics insiders are expecting a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for Radiopharm Theranostics (2 make us uncomfortable!) that we believe deserve your full attention.
But note: Radiopharm Theranostics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
PTX Metals Inc. Reports Further Highly Encouraging Drilling Results at Its W2 Cu-Ni-PGE and Gold Project
Toronto, Ontario--(Newsfile Corp. - June 3, 2025) - PTX Metals Inc. (TSXV: PTX) (OTCQB: PANXF) (FSE: 9PX) ("PTX" or the "Company"), a mineral exploration company focused on Cu-Ni-Au-PGE and Gold projects in Ontario, is pleased to release the following assay results from its Phase 1 of 2025 drilling program at the W2 Cu-Ni-PGE and Gold Project located in the Ring of Fire, northwestern Ontario, Canada (the "W2 Project"). Subsequently to the previous press release of May 27th, 2025, drill holes W225-08 and W225-12 are now being reported. Drilling has confirmed the presence of high-grade copper in multiple intervals above 1% Cu and consistent copper and nickel mineralization over broad widths in both drill holes W225-08 and W225-12. Additionally, drillhole W225-12 located in the CA2 zone of the Central Target, notably intercepted higher-grade palladium and platinum mineralization. This drill program has shown an improvement of both widths and grades from historical holes. Results from PTX's drilling include intersecting wide intercepts of encouraging grades near surface that continue to validate the potential of the exploration target issued last September, supporting a potential large bulk tonnage project. The results demonstrate a larger-scale system (~8 km in strike length) that encompasses the CA zones and the AP zones and a current goal to build a continuous system between CA1 and CA2 zones (see 3D geological model interpretation released on May 7th). Highlights - Drill Holes W225-08 and W225-12: Drillhole W225-08 intercepted a core length of 97.05m in the CA1 zone of near surface mineralization starting at 26.95m directly after the overburden. Drill hole W225-12, located in the CA2 zone 2.92 km to the East of CA1 zone, intersected 88.00m of sulphide mineralization demonstrating consistency of the mineralized body within the different identified zones. The highest grades by individual commodity in the two holes combined include: 1.80% copper, 0.74% nickel, 0.52 g/t gold, 1.05 g/t palladium and 0.55 g/t platinum and Cobalt 0.15% Drillhole W225-08 Drillhole W225-12 Table 1: Selected Results from drill holes W225-08 and W225-12. Intervals reported as core lengths. True widths are unknown at this time. To view an enhanced version of this graphic, please visit: Historical drilling was selective in assaying for all commodities and selective sampling procedures occurred. As a result, the Company has systematically assayed for Copper, Nickel, Gold, Palladium, Platinum and Cobalt and is now not reporting using Metal Equivalents and seen substantial improvements in the widths of mineralization with these practices. Additionally, for simplification purposes, Cu+Ni (%) and Au+Pt+Pd (g/t) are reported below as the arithmetic sum of individual commodity per interval chosen. Individual grades by commodity are also shown in table 1. Drill hole Analysis and Images: Drillhole W225-08, drilled into the CA1 Zone, was designed to infill and as a step out of hole 54004-0 drilled by Inco to the south, which reported some of the highest copper grade on the property [1] and a wide interval of consistent Nickel grade. The target was successfully intercepted starting from surface below the overburden at 26.95m depth and with 97.05m of mineralization within the main interval. Drilling has confirmed the presence of high-grade copper in multiple intervals above 1% Cu with up to 1.80% Cu and Nickel ranging between 0.20% and 0.70% within the mineralized interval as reported in Table 1 and in Figure 2. Drillhole W225-12 was designed to infill and as a step out of 130m to the east of W225-11 previously reported on May 27th, 2025. Both of PTX's holes showed not only higher-grade intervals but also a significant amount of palladium and platinum, where high-grade of 1.05g/t Pd was assayed in hole W225-12. Overall, the polymetallic system including copper, nickel, gold, platinum, palladium and cobalt occurs within consistent and similar wide intervals as shown in Figure 3. Figure 1: Plan Map showing CA1 and CA2 Zones along with drill hole locations for W225-08 and W225-12. Drillhole collars information is detailed in Table 2. Background is the reduced-to-pole total magnetic intensity (RTPTMI) derivative from the most recent Heli-GT 2025 magnetic survey. To view an enhanced version of this graphic, please visit: Figure 2: Cross section of drill hole W225-08, confirming historical drilling results in the CA1 zone previously intercepted in historical drill hole 54004-0. Refer to [1] below for historical drillholes data. To view an enhanced version of this graphic, please visit: Figure 3: Comparison side by side of grade of (Cu+Ni) and (Au+Pd+Pt) for drill hole W225-12. PGEs mineralization extends over 157m depth. To view an enhanced version of this graphic, please visit: High-grade individual commodity intersections within drill Hole W225-08 include: 1.53% Copper over 1.10 m from 50.85 m to 51.95 m 0.69% Nickel over 1.00 m from 43.00 m to 44.00 m 0.32 g/t Gold over 1.00 m from 114.00 m to 115.00 m 0.15 g/t Platinum over 0.57 m from 116.82 m to 116.82 m 0.41 g/t Palladium over 0.50 m from 137.94 m to 138.44 m 0.15 % Cobalt over 0.50 m from 64.50 m to 65.00 m High-grade individual commodity intersections within drill Hole W225-12 include: 1.80% Copper over 0.55 m from 105.61 m to 106.16 m 0.71% Nickel over 0.72 m from 99.33 m to 100.05 m 0.52 g/t Gold over 1.00 m from 56.00 m to 57.00 m 1.05 g/t Palladium over 1.00 m from 70.00 m to 71.00 m 0.55 g/t Platinum over 0.57 m from 102.91 m to 103.48 m 0.09 % Cobalt over 0.75 m from 102.16 m to 102.91 m Table 2: Drill Hole Collar Information Datum used in UTM NAD83 Z16N. DRILL OLE Easting Northing Elev (m) Azimuth Dip Length (m) W225-08 459,696 5,813,155 246 180 -55 146.00 W225-12 462,556 5,812,549 242 225 -55 159.00 [1] Data from historical drillhole were referred from a NI 43-101 report titled "NI 43-101 Updated Technical Report on the W2 Copper-Nickel-PGE Property" authored by I.A. Osmani et al., effective on September 4th, 2024. QAQC: Samples (NQ core diameter = 4.76 cm) were cut using a diamond blade saw, inserted into labeled bags, and delivered by representatives of PTX to Activation Laboratories Ltd. in Thunder Bay, Ontario. Activation Laboratories Ltd. is an ISO 17025:2005 accredited testing laboratory. Samples were analyzed for Au, Pt, and Pd using the lead fire-assay 1C-OES package, and multi-element analysis was completed by near-total digestion (four-acid) with an ICP-OES finish (1F2 package). For over-range samples (Cu, Ni) over 1% Cu or Nickel, the 8-4 Acid Near Total ICP-OES method was utilized. PTX inserted standards and blanks and performs duplicate analysis as part of its QA/QC program. Activation Laboratories also performs an internal QA/QC program which includes the insertion of CRM's, blanks, sample repeats, and duplicate samples. Qualified Person: The technical information presented in this news release has been reviewed and approved by Joerg Kleinboeck, P. Geo., a non-independent qualified person to PTX Metals who is responsible for ensuring that the related technical information provided in this news release is accurate and who act as a "qualified person" (QP) as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects. About PTX Metals Inc.: PTX is a mineral exploration company focused on high-quality strategic metals assets in northern Ontario, allowing exposure for shareholders to Copper, Gold, Nickel, and PGEs discovery. The Province of Ontario is renowned as a first-class mining jurisdiction for its abundance of mineral resources and safe jurisdiction. Our corporate objective is to advance our assets, and unveil the potential of two Flagship Projects, the W2 Cu-Ni-PGE located in the strategic Ring of Fire region, and the Shining Tree Gold Project neighbor to multi-million ounces gold deposits in the Timmins Gold Camp. PTX's portfolio of assets was strategically acquired for their geologically favorable attributes, and proximity to established mining companies. PTX is based in Toronto, Canada, with a primary listing on the TSX under the symbol PTX. The Company is also listed in Frankfurt under the symbol 9PF and on the OTCQB in the United States as PANXF. For additional information on PTX, please visit the Company's website at For further information, please contact: Greg Ferron, President and Chief Executive Officer Phone: +1 (416) 270-5042 Email: gferron@ Forward-Looking Information: This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information, including statements regarding the ability of the Company to satisfy the regulatory, stock exchange and commercial closing conditions of Private Placement, and the potential development of mineral resources and mineral reserves which may or may not occur. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and general economic and political conditions. Forward looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary approvals, including governmental and regulatory approvals, will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information, future events or otherwise, other than as required by applicable laws. For more information on the risks, uncertainties and assumptions that could cause our actual results to differ from current expectations, please refer to the Company's public filings available under the Company's profile at This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
an hour ago
- Associated Press
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix's theranostic candidates. In-person attendance is open to institutional investors and analysts: Advance registration is required for in person attendance. Please RSVP by sending an email to [email protected]. To register for the live webcast: ___________________ 1 Response Assessment in Neuro-Oncology. 2 Society for Neuro-Oncology. 3 Brand name subject to final regulatory approval. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). TLX591, TLX101 and TLX250-CDx have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected] Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: [email protected] Lisa Wilson In-Site Communications Email: [email protected] Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Yahoo
an hour ago
- Yahoo
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix's theranostic candidates. Prostate cancer therapy (TLX591): Oliver Sartor, MD, is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, and led or co-led multiple national and international clinical studies, including four Phase 3 studies pivotal for FDA approval for Bayer, Novartis and Sanofi in advanced prostate cancer. Glioblastoma therapy (TLX101): John de Groot, MD, is an internationally recognized expert in neuro-oncology, spending over 20 years working in the space at MD Anderson Cancer Center, where he led the neuro-oncology clinical research group. He has been at University of California, San Francisco (UCSF) since 2021 where he is a Professor in Residence in the Department of Neurology, and the Chief of the Division of Neuro-Oncology. Dr. de Groot has over 200 peer-reviewed publications and has led or been involved in multiple national and internal clinical studies, as well as involved in key neuro-oncology societal guidelines development from RANO1, and SNO2. Renal cancer imaging (TLX250-CDx, Zircaix®3): Joseph Osborne, MD, Ph.D. is the Chief of Molecular Imaging and Therapeutics and a Professor of Radiology at Weill Cornell Medicine. Dr. Osborne leads the Radioligand Therapy Laboratory at Weill Cornell, which is focused on advancing molecular imaging in alignment with precision medicine. He has also served as principal investigator on an academic-industrial R01 NIH grant to improve access to 68Ga-labeled pharmaceuticals and is the Assistant Director of clinical trial participation at the Meyer Cancer Center. In-person attendance is open to institutional investors and analysts: Advance registration is required for in person attendance. Please RSVP by sending an email to To register for the live webcast: ___________________1 Response Assessment in Neuro-Oncology.2 Society for Neuro-Oncology.3 Brand name subject to final regulatory approval. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). TLX591, TLX101 and TLX250-CDx have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.) Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: Lisa Wilson In-Site Communications Email: lwilson@ Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
